Bio-better avoids preliminary injunction in Germany - .PDF file.
The first preliminary injunction decision in Germany relating to a ‘bio-better’-type drug has been made in Amgen v Teva in the Düsseldorf District Court. The injunction was rejected and an appeal is pending.
The product of Amgen, Lipegfilgastrim, the owner of the patent for which enforcement was sought, was not itself covered by the patent…
If you are registered and logged in to the site, click on the link below to read the rest of the Taylor Wessing briefing. If not, please register or sign in with your details below.